Pharmabiz
 

Crucell inks PER.C6 licensing agreement with GSK

Sittard, NetherlandsTuesday, August 17, 2004, 08:00 Hrs  [IST]

Dutch biotechnology company Crucell N.V. and allied contract manufacturer DSM Biologics announced that Crucell has signed a PER.C6 research license agreement with GlaxoSmithKline. This license allows GlaxoSmithKline to use Crucell's PER.C6 technology in research and preclinical development related to its portfolio of recombinant monoclonal antibody products. Under the terms of the agreement, Crucell and DSM Biologics will receive an upfront payment and annual maintenance fees. Further financial details were not disclosed, release from Crucell N.V said. Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine.

 
[Close]